Decapeptide-12 vs Orforglipron
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Decapeptide-12GLP-1 / Weight Loss Agonists
Orforglipron- Summary
- Decapeptide-12 is a synthetic 10-amino acid peptide developed for skin brightening and depigmentation. It selectively inhibits tyrosinase activity and downstream melanogenesis pathways, reducing hyperpigmentation, dark spots, and uneven skin tone without the irritation associated with hydroquinone.
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Half-Life
- Not applicable (topical)
- ~12 hours (once-daily oral dosing)
- Admin Route
- Topical
- Oral
- Research
- —
- —
- Typical Dose
- 5 ppm (0.0005%) concentration
- 12 mg → 24 mg → 36 mg → 45 mg
- Frequency
- Twice daily (AM and PM)
- Once daily
- Key Benefits
- Reduces hyperpigmentation and dark spots
- Evens skin tone and improves radiance
- Inhibits post-inflammatory hyperpigmentation
- Well-tolerated alternative to hydroquinone
- Effective for melasma and age spots
- Non-cytotoxic to melanocytes
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Side Effects
- Generally very well-tolerated
- Rare mild irritation or sensitivity in some skin types
- Results may take several weeks to become visible
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Stacks With
- —
- —